What did @socalurologyinstitute actually say?
The creator, apparently a urologist, argued that weekly testosterone injections are perfectly valid for many men and that social media pressure toward twice-weekly or daily dosing is "misinformation." Their logic: if you feel fine on day five, six, or seven, there is no clinical reason to split your dose. If you do notice an energy or mood drop mid-week, then breaking into two injections makes sense. The takeaway was essentially individualize based on symptoms, not dogma.
That is a more nuanced position than the headline framing suggests. They are not saying weekly is always better. They are saying it is not always worse, and that personal response should drive the decision. That is a reasonable clinical stance, and it deserves a fair hearing rather than a reflexive dismissal.
Does the science back this up?
Mostly, yes. Testosterone cypionate has a published half-life of roughly seven to eight days, meaning a weekly injection does maintain measurable serum levels throughout the dosing interval for most men. The pharmacokinetics are well-documented. Spratt et al. (2017, Journal of Clinical Endocrinology and Metabolism) confirm that peak-to-trough variability exists but is tolerable in a significant subset of patients.
Where the evidence gets more interesting is in symptom correlation. Ramasamy et al. (2014, Journal of Urology) found that men on weekly injections reported mood and energy fluctuations that correlated with trough testosterone levels. That does not mean everyone experiences this, but it is not a fringe concern. The creator implicitly acknowledges this by advising patients who do feel a drop to switch to twice-weekly dosing, which is exactly the clinically appropriate response. The science supports the individualized approach here.
What did they get wrong (or right)?
They got the core message right. Weekly injections are a legitimate, guideline-supported option. The Endocrine Society clinical practice guidelines for male hypogonadism (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) do not mandate any specific injection frequency for cypionate or enanthate. The prescriber and patient decide based on response.
What the creator overstated was labeling all advice favoring more frequent injections as "misinformation." That word has a specific meaning. Saying twice-weekly dosing produces more stable serum levels is not misinformation, it is pharmacokinetically accurate. Nieschlag and Behre (2012, Testosterone: Action, Deficiency, Substitution) document that more frequent, smaller doses reduce peak-to-trough amplitude. Recommending that approach is not spreading false information. It is a reasonable clinical preference. The creator probably meant to say it is not universally necessary, which is fair, but the word choice was sloppy and undermines an otherwise solid point.
What should you actually know?
Injection frequency for testosterone cypionate or enanthate is genuinely individualized medicine. There is no single correct answer. Weekly injections maintain therapeutic levels for many men. Twice-weekly injections reduce hormonal variability, which some men find improves mood stability and libido consistency. Neither approach is categorically superior for every patient.
Your symptoms on day four through seven are actual data. If you feel fine, weekly is likely working. If you notice fatigue, irritability, or low libido mid-week, a split dose is worth discussing with your prescriber. What you should not do is adjust your own dose or frequency based on a TikTok video, including this one. Serum levels, hematocrit, estradiol, and PSA all require monitoring. Frequency changes should involve a clinical conversation, not a solo decision.
- Testosterone cypionate half-life: approximately 7-8 days (Spratt et al., 2017)
- Peak levels typically occur 24-72 hours post-injection
- Trough variability is real but individually variable
- More frequent dosing does reduce peak-to-trough amplitude, which is not misinformation
- Symptom-guided frequency adjustment is clinically supported